rna
interfer
rnai
power
approach
reduc
express
endogen
express
protein
wide
use
biolog
applic
har
silenc
mrna
encod
pathogen
protein
therapi
variou
methodsinclud
deliv
rna
oligonucleotid
express
rnai
trigger
viral
vector
develop
success
rnai
cell
cultur
vivo
recent
rnaibas
gene
silenc
approach
demonstr
human
ongo
clinic
trial
hold
promis
treat
fatal
disord
provid
altern
tradit
small
molecul
therapi
describ
broad
rang
approach
achiev
target
gene
silenc
therapi
discuss
import
consider
develop
rnai
trigger
use
human
review
current
statu
clinic
trial
rna
interfer
rnai
natur
cellular
process
regul
gene
express
provid
innat
defenc
mechan
invad
virus
transpos
element
find
dsrna
initi
rnai
among
signific
recent
contribut
cell
biolog
sinc
discoveri
rnai
mediat
nucleotid
nt
duplex
research
work
har
potenti
address
biolog
question
treat
human
diseas
reagent
small
interf
rna
sirna
appli
directli
cell
tissu
organ
other
engin
express
cell
hairpin
structur
provid
sirna
process
basic
premis
underli
broad
util
rnai
theori
design
sirna
vector
encod
target
virtual
gene
interest
rnai
technolog
use
cell
natur
machineri
move
exogen
appli
sirna
appropri
cellular
compart
encount
correct
mrna
target
induc
degrad
initi
work
rnai
fli
worm
move
quickli
larger
mammal
fuell
excit
potenti
clinic
applic
howev
similar
way
develop
field
human
therapi
geneand
antibodytherapi
earli
excit
temper
realist
understand
emerg
mileston
must
reach
eventu
approv
human
therapi
recent
year
variou
complex
barrier
achiev
effici
rnai
becom
evid
hurdl
includ
specif
target
gene
deliveri
correct
cell
tissu
durabl
rnai
activ
abil
redos
need
consider
stabil
target
mrna
encod
protein
also
becom
awar
problem
pose
variou
platform
use
elicit
rnai
howev
setback
come
opportun
exampl
earli
work
sirna
appli
mous
airway
epitheli
cell
reduc
viral
burden
vivo
elicit
inhibit
target
gene
express
later
found
induct
innat
immun
respons
probabl
contribut
efficaci
experi
alter
chemic
makeup
synthet
rna
diminish
immun
respons
avoid
known
proinflammatori
sequenc
find
also
open
investig
eye
possibl
purpos
use
immunostimulatori
rnai
direct
therapeut
adjuv
although
clinic
util
rnai
yet
realiz
ongo
patient
trial
provid
opportun
success
number
rnaibas
preclin
clinic
trial
grown
past
sever
year
includ
studi
retin
degener
dominantli
inherit
brain
skin
diseas
viral
infect
respiratori
disord
cancer
metabol
diseas
tabl
provid
overview
rnai
discuss
strategi
use
pathway
direct
gene
silenc
therapi
describ
deliveri
system
might
suitabl
differ
circumst
bring
reader
attent
issu
must
surmount
widespread
use
vivo
rnainduc
silenc
complex
risc
risc
group
protein
includ
one
argonaut
protein
induc
target
mrna
cleavag
base
load
small
interf
rna
microrna
guid
strand
develop
rnai
therapi
base
understand
small
rna
biogenesi
pathway
two
main
type
small
rna
involv
gene
silenc
microrna
mirna
sirna
process
target
summar
fig
detail
found
recent
review
mirna
sirna
mirna
mediat
posttranscript
gene
silenc
process
endogen
express
transcript
fig
either
process
strand
mediat
posttranscript
gene
silenc
mani
mirna
show
asymmetri
primarili
load
one
strand
rnainduc
silenc
complex
risc
small
rna
guid
risc
mrna
target
mirna
typic
bind
utr
watsoncrick
base
pair
mirna
target
usual
partial
high
complementar
base
mirna
known
seed
region
recent
data
suggest
base
pair
also
occur
central
mirna
nucleotid
target
mrna
data
sever
laboratori
show
mirna
repress
initi
translat
although
recent
work
indic
mirnamrna
complex
transport
cytoplasm
process
bodi
deadenyl
mrna
degrad
occur
interestingli
mirnamedi
translat
repress
revers
activ
phase
ii
apob
apolipoprotein
b
bcell
clllymphoma
cc
chemokin
receptor
type
ldl
lowdens
lipoprotein
also
known
proteasom
subunit
beta
type
also
known
proteasom
subunit
beta
type
also
known
proteasom
subunit
beta
type
pharm
pharmaceut
protein
kinas
pololik
kinas
ribonucleosidediphosph
reductas
subunit
rsv
respiratori
syncyti
viru
also
known
dna
damageinduc
transcript
protein
vegf
vascular
endotheli
growth
factor
clinicaltrialsgov
figur
mirna
sirna
pathway
rnai
mammal
primari
microrna
primirna
transcrib
rna
polymeras
trim
microprocessor
complex
compris
drosha
microprocessor
complex
subunit
nucleotid
precursor
call
premirna
left
side
figur
mirna
also
process
splice
short
intron
known
mirtron
premirna
contain
loop
usual
interspers
mismatch
along
duplex
premirna
associ
exportin
export
cytoplasm
complex
contain
dicer
tar
rnabind
protein
trbp
also
known
pact
also
known
prkra
process
premirna
mirnamirna
duplex
duplex
associ
argonaut
ago
protein
within
precursor
rnaiinduc
silenc
complex
prerisc
one
strand
duplex
passeng
strand
remov
matur
risc
contain
guid
strand
direct
complex
target
mrna
posttranscript
gene
silenc
seed
region
mirna
indic
rnai
trigger
design
offtarget
potenti
sequenc
need
consid
long
dsrna
right
side
figur
process
dicer
trbp
pact
small
interf
rna
sirna
sirna
rna
harbour
phosphat
po
group
dinucleotid
overhang
within
prerisc
complex
ago
protein
cleav
passeng
sirna
strand
matur
risc
contain
ago
protein
guid
strand
associ
target
mrna
cleavag
inset
show
properti
sirna
thermodynam
stabil
termin
sequenc
direct
strand
load
like
natur
occur
artifici
engin
mirna
potenti
seed
region
sourc
mirnalik
offtarget
silenc
shrna
short
hairpin
rna
sequenc
seven
base
microrna
complementari
mrna
target
sequenc
essenti
initi
bind
microrna
target
seed
also
exist
arbitrarili
small
interf
rna
process
short
hairpin
rna
caus
micrornalik
silenc
primirna
initi
transcript
product
microrna
gene
gener
nucleotid
long
may
contain
one
microrna
stem
loop
process
microrna
biogenesi
pathway
premirna
hairpin
precursor
microrna
form
cleavag
primari
microrna
drosha
member
rnase
iii
famili
ribonucleas
cleav
dsrna
small
interf
rna
precursor
microrna
mirtron
microrna
innat
immun
respons
dsrna
ssrna
cpg
dna
stimuli
trigger
protect
antivir
respons
host
cell
signal
elicit
releas
activ
multipl
compon
innat
adapt
immun
tlr
famili
receptor
recogn
pathogenassoci
molecular
pattern
pamp
includ
dna
rna
molecul
immunostimulatori
dinucleotid
motif
interact
tolllik
receptor
stabl
nucleic
acid
lipid
particl
snalp
lipid
nanoparticl
formul
system
deliveri
small
interf
rna
tissu
sirna
small
dsrna
nt
length
process
longer
dsrna
fig
one
strand
guid
strand
direct
silenc
strand
passeng
degrad
strand
becom
determin
thermodynam
properti
duplex
sirna
gener
show
full
complementar
target
mrna
cleavag
occur
base
end
guid
strand
bind
site
understand
small
rna
biogenesi
enabl
develop
sever
strategi
har
rnai
pathway
therapi
recombin
inhibitori
rna
design
mimic
primari
mirna
primirna
case
artifici
mirna
exogen
mirna
precursor
mirna
premirna
case
short
hairpin
rna
shrna
wherea
chemic
synthes
rna
oligonucleotid
design
mimic
dicer
product
substrat
class
mediat
gene
silenc
enter
pathway
differ
step
fig
main
differ
exogen
appli
oligonucleotid
sirna
hairpinbas
speci
shrna
mirna
shuttl
mode
deliveri
durat
gene
silenc
tabl
howev
recent
advanc
nonvir
viral
system
blur
distinct
follow
section
describ
main
strategi
design
deliveri
inhibitori
rna
common
method
use
har
rnai
pathway
target
gene
silenc
transfect
nt
sirna
cell
anoth
option
use
longer
nt
duplex
process
dicer
sirna
call
dicerreadi
sirna
case
silenc
potenc
dicerreadi
sirna
greater
sirna
synthet
trigger
transfect
gener
accomplish
high
effici
cell
line
use
commerci
avail
transfect
reagent
howev
discuss
altern
packag
often
requir
deliveri
primari
cell
vivo
applic
ration
sirna
design
import
consid
sirna
sequenc
chemic
natur
silenc
moieti
exampl
rna
without
modifi
base
sugar
length
rna
natur
end
vitro
synthesi
sirna
use
polymeras
creat
triphosph
induc
type
interferon
respons
type
ifn
respons
similarli
bluntend
sirna
induc
cytoplasm
retino
acid
induc
gene
protein
also
known
ifn
product
chemic
synthes
sirna
lack
triphosph
contain
appropri
overhang
allevi
issu
mani
sirna
although
abl
reduc
express
target
gene
immunostimulatori
sequenceindepend
manner
recogn
pattern
recognit
tolllik
receptor
tlr
endosom
cell
surfac
recogn
dsrna
activ
uncomplex
sirna
activ
inhibit
blood
lymphat
vessel
growth
advantag
set
corneal
vascular
inhibit
angiogenesi
desir
tlr
activ
also
advantag
cancer
therapi
stimul
dendrit
cell
respond
immunolog
cancer
cell
recent
gener
unwant
stimul
tlr
oligonucleotid
use
cleverli
achiev
gene
silenc
immun
stimul
cancer
therapi
wellcharacter
cpg
oligonucleotid
agonist
fuse
sirna
target
immun
suppressor
promot
antitumour
immun
respons
mice
interest
combin
tumour
target
sirna
immunostimulatori
therapi
may
substanti
augment
promis
clinic
result
use
agonist
alon
tlr
activ
would
contraind
set
attempt
revert
inhibit
ischaemia
addit
endosom
recogn
ssrna
activ
sirna
complex
carrier
intern
taken
receptor
target
alter
chemic
natur
sirna
dramat
reduc
tlr
respons
elicit
exogen
appli
sirna
exampl
use
purin
nucleosid
passeng
strand
reduc
ifn
induct
retain
target
specif
modif
also
improv
serum
stabil
reduc
suscept
rnase
sirna
deliveri
option
chemic
modifi
sirna
often
packag
carrier
system
deliveri
neg
charg
size
prevent
cellular
penetr
uncomplex
sirna
deliv
system
also
readili
clear
kidney
excret
array
carrier
vast
excel
summari
chemic
makeup
biolog
properti
found
elsewher
among
common
lipidbas
carrier
cholesterol
conjug
sens
strand
duplex
cholesterolconjug
sirna
commerci
avail
enabl
improv
uptak
liver
bound
lowdens
lipoprotein
ldl
serum
ldl
uptak
liver
robust
lipophil
sirna
also
bind
highdens
lipoprotein
hdl
target
sirna
tissu
hdl
receptor
gut
kidney
vagin
epitheli
cell
oligodendrocyt
brain
excit
data
nonhuman
primat
show
singl
deliveri
sirna
complex
stabl
nucleic
acid
lipid
particl
snalp
reduc
target
gene
express
almost
week
recent
deliveri
strategi
use
success
protect
nonhuman
primat
lethal
challeng
ebola
viru
use
sirna
target
express
three
ebola
viru
protein
improv
snalp
reduc
dose
requir
effect
silenc
nonhuman
primat
tenfold
augment
clinic
util
reagent
complex
sirna
carrier
also
provid
opportun
target
specif
cell
case
cancer
tumour
bed
first
inhuman
studi
nanoparticl
design
enhanc
uptak
cancer
cell
use
transferrinreceptortarget
ligand
show
reduc
level
target
mrna
evid
sirnamedi
cleavag
target
studi
continu
interest
learn
pharmacokinet
sirna
addit
patient
see
clinic
effect
therapi
carrier
tissuespecif
target
includ
aptam
antibodi
peptid
protein
oligonucleotid
agonist
synthet
link
sirna
case
oligonucleotid
peptid
aptam
wherea
other
part
complex
carrier
system
review
ref
express
system
rnai
trigger
shrna
artifici
mirna
express
shrna
artifici
mirna
achiev
deliv
plasmid
use
bacteri
viral
vector
rnai
trigger
transcrib
sens
antisens
sequenc
connect
loop
unpair
nucleotid
mimic
premirna
shrna
primirna
artifici
mirna
follow
transcript
artifici
mirna
process
complex
export
cytoplasm
engag
prerisc
complex
via
normal
mirna
biogenesi
pathway
fig
cleavag
passeng
nonguid
strand
guid
strand
direct
risc
mrna
target
although
goal
shrna
make
premirna
mimic
shrna
transcript
often
reflect
drosha
cleavag
product
contain
typic
dinucleotid
overhang
transport
exportin
impair
reduc
shrna
export
could
caus
nuclear
accumul
toxic
altern
exportin
recogn
duplex
shrna
express
except
high
rel
endogen
mirna
exportin
becom
satur
overexpress
exportin
allevi
blockag
satur
downstream
process
pathway
occur
one
method
allevi
satur
exportin
argonaut
protein
overexpress
concomitantli
shrna
howev
therapeut
purpos
might
appropri
use
weaker
promot
artifici
mirna
mirna
hairpin
embed
larger
transcript
artifici
mirna
approach
suit
shrna
rna
polymeras
iibas
express
system
provid
tissuespecif
induc
gene
silenc
product
rnai
express
system
need
assess
care
ascertain
whether
desir
strand
load
risc
well
rna
express
process
fig
rnai
triggerexpress
plasmid
packag
mani
carrier
use
sirna
deliveri
although
natur
particl
chang
differ
cargo
larg
dna
versu
small
rna
sever
nonvir
platform
gene
deliveri
investig
review
ref
sirna
commerci
reagent
avail
plasmid
transfect
cell
line
primari
cell
vitro
figur
workflow
test
therapeut
rnai
trigger
cartoon
depict
luciferas
report
system
use
confirm
appropri
strand
small
interf
rna
sirna
stemloop
platform
rnai
express
system
load
rnainduc
silenc
complex
risc
plasmid
luciferas
report
harbour
sequenc
complementari
guid
strand
utr
cotransfect
rnai
system
appropri
guid
strand
load
luciferas
activ
diminish
report
contain
sequenc
complementari
passeng
strand
cotransfect
luciferas
activ
reduc
silenc
base
microrna
mirna
like
mechan
inhibit
luciferas
activ
indic
risc
load
independ
sequenc
abil
induc
target
cleavag
b
northern
blot
analysi
use
evalu
rnai
trigger
express
vector
short
hairpin
rna
shrna
primari
mirna
primirna
mimic
poorli
process
express
effici
buildup
shrna
may
occur
lane
appropri
process
yield
readili
detect
matur
process
sirna
minim
level
unprocess
materi
lane
northern
blot
probe
passeng
strand
also
use
assess
risc
load
unintend
strand
shown
c
small
rna
quantit
pcr
quantifi
matur
product
yield
inform
overal
level
matur
product
import
know
understand
dose
figur
show
exampl
result
obtain
effect
poorli
process
rna
precursor
clone
sequenc
matur
small
rna
use
assess
silenc
rna
detail
shown
ct
threshold
cycl
outer
protein
coat
viru
adenoassoci
viru
adenoviru
bacteria
use
innov
platform
rnai
deliveri
approach
built
earlier
work
show
therapeut
bacteria
enter
tumour
patient
cancer
presum
via
permiss
vasculatur
basic
premis
recombinantli
engin
escherichia
coli
enter
mammalian
cell
vivo
deliveri
transfer
shrna
bacteria
contain
plasmid
express
shrna
target
fed
mice
express
reduc
intestin
epithelium
platform
clinic
test
famili
adenomat
polyposi
inherit
form
colon
cancer
relat
approach
mice
use
minicel
deriv
salmonella
enterica
subsp
enterica
serovar
typhimurium
target
tumourcellsurfac
receptor
deliv
sirna
shrna
method
reduc
tumour
burden
improv
mous
surviv
viral
vector
use
deliv
shrna
artifici
mirna
includ
murin
oncoretrovirus
lentivirus
adenovirus
adenoassoci
virus
aav
herpesvirus
among
other
tabl
refer
reader
recent
review
describ
biolog
product
vector
system
highlight
major
differ
among
tool
relev
use
rnaibas
applic
respect
tissu
tropism
fate
recombin
genom
host
cell
genom
recombin
adenovirus
aav
gener
remain
episom
viru
enter
host
cell
viral
capsid
uncoat
nucleocapsid
transport
cell
nucleu
advantag
vector
system
genom
remain
episom
insert
mutagenesi
avoid
howev
unless
transient
express
desir
use
limit
cell
divid
slowli
exampl
epitheli
cell
exampl
neuron
episom
genom
lost
follow
cell
divis
natur
occur
differ
capsid
structur
among
adenovirus
mirna
precursor
microrna
premirna
process
dicer
gener
mirna
duplex
contain
mirna
strand
mirna
strand
one
load
rnainduc
silenc
complex
risc
ratio
one
strand
load
risc
mediat
silenc
activ
vari
among
speci
tissu
diseas
development
set
detect
phenotyp
chang
trigger
rnai
treatment
deriv
directli
indirectli
silenc
target
mrna
among
aav
affect
abil
virus
infect
divers
cell
type
vitro
specif
cell
within
tissu
capsid
gene
also
manipul
artifici
alter
tropism
cell
surfac
molecul
tissu
choic
capsid
retarget
take
advantag
fact
bind
establish
virus
use
secondari
receptor
intern
major
differ
adenovirus
aav
packag
capac
kb
aav
compar
kb
although
usual
less
kb
adenovirus
anoth
distinguish
point
viral
gene
remov
aav
vector
genom
wherea
recombin
adenovirus
often
express
mani
viral
gene
may
induc
immun
respons
transduc
cell
caus
subsequ
elimin
reason
aav
gener
use
achiev
rnai
cell
one
want
save
wherea
adenovirus
use
tool
either
transient
express
immun
induct
desir
notabl
adenovirus
aav
infect
cell
multipl
copi
per
cell
problemat
shrna
instead
artifici
mirna
dose
may
amplifi
dose
function
copi
number
effici
hairpin
express
process
mani
case
higher
express
necessarili
benefici
hairpin
inappropri
process
express
high
level
toxic
box
andor
satur
rnai
machineri
occur
see
lentivirus
anoth
deliveri
option
rna
genom
contain
hairpin
cleav
rna
process
enzym
problem
vector
product
howev
neg
effect
vector
titr
rescu
inhibit
rnai
pathway
express
cassett
placement
also
import
lentivirus
express
shrna
artifici
mirna
configur
neg
affect
vector
product
shrna
express
recombin
lentivirus
transduc
divid
nondivid
cell
gener
integr
transcript
activ
chromatin
potenti
problem
insert
could
activ
oncogen
inactiv
tumour
suppressor
gene
insert
promiscu
dramat
reduc
use
integrasedefect
lentivirus
like
adenovirus
aav
vector
tropism
lentivirus
alter
case
manipul
viral
envelop
use
vector
product
obviou
applic
recombin
lentivirus
transduct
vitro
case
clinic
applic
ex
vivo
gene
transfer
haematopoiet
progenitor
cell
peripher
blood
lymphocyt
treatment
viral
infect
set
recombin
lentivirus
appli
cell
vector
per
cell
higher
concentr
often
toxic
final
number
integr
per
cell
approxim
copi
per
cell
fact
import
consid
lentivirus
rnai
deliveri
copi
number
low
shrna
express
strong
promot
may
prefer
import
consider
therapeut
rnai
gene
silenc
approach
rare
remov
transcript
offtarget
silenc
occur
box
target
organ
cell
type
target
transcript
present
uniqu
challeng
case
goal
target
everi
cell
organ
instanc
promiscu
cell
tropism
disadvantag
exampl
one
might
wish
target
cancer
cell
gene
silenc
avoid
normal
surround
tissu
express
therapeut
rna
hepatocyt
cell
deliveri
liver
tissu
specif
achiev
case
incorpor
ligand
carrier
direct
transfect
infect
desir
cell
describ
altern
research
taken
advantag
natur
tropism
modifi
tropism
viral
vector
cell
tissu
target
use
cellspecif
promot
express
silenc
rna
design
therapeut
strategi
involv
small
interf
rna
sirna
expressionbas
system
import
know
detail
rna
strand
incorpor
rnainduc
silenc
complex
risc
mediat
silenc
genom
encod
microrna
mirna
mammalian
cell
possess
necessari
inform
within
mirna
duplex
appropri
load
mirna
mirna
strand
use
chemic
synthes
sirna
system
express
short
hairpin
rna
artifici
mirna
design
must
take
account
natur
taught
us
exampl
design
consid
whether
artifici
mirna
end
necessari
appropri
process
export
whether
subsequ
biochem
process
result
load
correct
strand
risc
sever
method
determin
strand
load
risc
includ
northern
blot
small
rna
pcr
luciferasebas
plasmid
system
target
guid
strand
passeng
strand
place
utr
report
fig
although
publicli
avail
algorithm
use
thermodynam
rule
silenc
rna
import
sequenc
express
construct
character
termini
sequenc
necessari
ascertain
rel
proport
intend
matur
silenc
rna
rna
result
cleavag
site
shift
one
sever
nucleotid
alter
rna
could
substanti
increas
offtarget
silenc
offtarget
silenc
occur
interact
seed
sequenc
transcript
harbour
complementari
sequenc
sirna
high
offtarget
potenti
base
seed
complement
frequenc
transcriptom
result
increas
silenc
unintend
mrna
toxic
problem
reduc
design
bia
risc
load
toward
correct
rna
strand
ensur
process
silenc
rna
precursor
produc
desir
small
rna
duplex
incorpor
chemic
modif
group
guid
passeng
strand
chemic
synthes
sirna
reduc
indiscrimin
effect
ssrna
dsrna
addit
incorpor
unlock
nucleic
acid
acycl
rna
mimic
make
rna
poor
ligand
tolllik
receptor
vari
amount
offtarget
silenc
occur
differ
silenc
platform
level
silenc
rna
vari
exampl
express
system
transfect
plasmid
transduct
adenovirus
adenoassoci
virus
yield
copi
per
cell
transduct
lentivirus
sirna
transfect
also
result
abund
offtarget
silenc
sirna
low
ontarget
potenc
moder
high
offtarget
potenti
see
less
offtarget
silenc
lentivirusbas
system
compar
sirna
report
recent
studi
use
high
dose
sirna
high
offtarget
potenti
macrophagelik
cell
resid
liver
involv
antigen
present
includ
asthma
chronic
obstruct
airway
diseas
cystic
fibrosi
addit
cell
key
site
interact
host
environ
mani
common
viral
pathogen
replic
cell
initi
step
life
cycl
provid
opportun
silenc
viral
gene
product
host
gene
modifi
viral
life
cycl
host
respons
viru
reason
fact
respiratori
tract
access
tissu
make
airway
epithelium
attract
tissu
explor
rnai
therapi
potenti
rnaibas
treatment
modifi
host
respons
respiratori
viru
infect
extens
studi
sever
highprofil
paper
publish
synthes
sirna
express
shrna
use
inhibit
influenza
viru
sever
acut
respiratori
syndrom
sar
coronaviru
respiratori
syncyti
viru
parainfluenza
viru
anim
model
studi
show
promis
potenti
pitfal
rnai
therapeut
strategi
although
respiratori
tract
readili
access
use
topic
aerosol
deliveri
techniqu
avail
clinic
sever
year
basic
clinic
studi
field
gene
therapi
humbl
investig
studi
use
number
wellconceiv
viral
nonvir
deliveri
techniqu
treat
monogenet
disord
cystic
fibrosi
treatment
hinder
physic
barrier
pose
epitheli
cell
addit
secret
host
defenc
mechan
principl
deliveri
rnai
oligonucleotid
might
pose
less
signific
challeng
express
plasmid
genet
payload
oligonucleotid
need
enter
cytoplasm
surfac
cell
function
addit
mucos
surfac
airway
alveoli
activ
site
innat
adapt
immun
rnai
deliveri
vector
rnai
oligonucleotid
may
elicit
immunolog
respons
context
antiinfect
rnai
strategi
immunostimul
confound
earli
preclin
result
possibl
ongo
clinic
data
addit
target
gene
product
respiratori
virus
sever
group
use
sirna
technolog
knock
express
host
gene
product
report
gene
respiratori
tract
anim
model
date
anim
studi
shown
littl
efficaci
poor
deliveri
also
demonstr
vitro
fulli
differenti
cell
model
studi
short
effect
rnai
activ
requir
applic
sirna
develop
welldifferenti
epitheli
barrier
thu
effici
deliveri
remain
import
hurdl
overcom
clinic
studi
develop
hiv
remain
attract
target
drug
develop
includ
therapi
base
rnai
exampl
strategi
includ
target
receptor
viru
viru
howev
errorpron
replic
cycl
hiv
problemat
combinatori
approach
includ
rnai
gene
silenc
approach
therefor
develop
hiv
approach
undergo
clinic
test
use
lentivir
vector
express
shrna
target
exon
share
hiv
tat
rev
gene
tatrev
common
exon
combin
two
hivspecif
rnabas
inhibitor
nucleolarloc
tar
rna
decoy
cc
chemokin
receptor
type
target
hammerhead
ribozym
strategi
transduc
haematopoiet
progenitor
cell
ex
vivo
reinfus
patient
earli
data
phase
trial
show
transduc
cell
success
engraft
within
day
four
patient
treat
importantli
treatmentrel
toxic
vector
express
document
month
multipl
cell
lineag
express
introduc
ribozym
shrna
rnai
recent
use
inhibit
lethal
infect
filoviru
ebola
primat
model
combin
modifi
sirna
target
ebola
l
polymeras
viral
protein
snalpformul
deliv
intraven
strategi
protect
anim
death
includ
receiv
sirna
onset
infect
rnaibas
therapi
also
develop
hepat
b
viru
hbv
hepat
c
viru
hcv
chronic
hepat
contribut
significantli
hepatocellular
carcinoma
pathogenesi
drive
interest
new
hbv
hcv
therapi
mean
reduc
diseas
burden
hiv
hepat
virus
high
mutat
frequenc
viral
replic
therefor
current
antivir
strategi
focu
deliveri
express
one
rnai
construct
achiev
success
chronic
hepat
infect
current
focu
sever
laboratori
use
mirna
shrna
express
method
target
one
viral
transcript
host
protein
also
target
exampl
sirna
direct
diacylglycerol
acyltransferas
reduc
hcv
virion
product
addit
inhibit
express
host
gene
product
pololik
kinas
use
sirna
reduc
hcv
replic
inhibit
also
use
anticanc
studi
see
promis
result
also
report
use
rnai
modifi
viru
host
gene
express
mous
model
genit
tract
herp
simplex
viru
infect
lipidcomplex
rna
oligonucleotid
inhibit
express
gene
host
receptor
nectin
also
known
approach
show
efficaci
prevent
treatment
infect
manipul
host
mirna
inhibit
viral
express
also
explor
see
discuss
rnai
neurolog
disord
bloodbrain
barrier
limit
access
central
nervou
system
cn
thu
practic
manner
silenc
target
neural
cell
direct
inject
rnai
trigger
sirna
short
halflif
redos
use
indwel
cathet
would
requir
chronic
diseas
howev
acut
ill
deliveri
brain
tumour
short
halflif
sirna
may
desir
contrast
viral
platform
provid
last
express
antagomir
rna
oligonucleotid
antisens
endogen
microrna
use
inhibit
micrornamrna
interact
may
ideal
chronic
disord
exampl
vector
express
therapeut
rnai
improv
diseas
phenotyp
mani
month
preclin
studi
rodent
model
polyglutamin
repeat
diseas
amyotroph
later
sclerosi
parkinson
diseas
alzheim
diseas
nonhuman
primat
brain
viralvectorbas
system
safe
given
encourag
result
aav
human
brain
eye
clinic
trial
neurodegen
diseas
aav
express
rnai
trigger
anticip
issu
consid
deliveri
correct
cell
type
brain
specif
neuron
versu
glia
achiev
uncomplex
sirna
fact
report
sirna
deliv
nonhuman
primat
brain
enter
oligodendrocyt
might
suitabl
method
therapi
aim
treat
multipl
sclerosi
white
matter
diseas
encapsid
viral
vector
natur
protein
coat
impart
natur
tropism
neuron
case
exampl
cell
type
envelop
viral
vector
lentivir
system
deriv
hiv
tropism
impart
envelop
use
vector
product
process
known
pseudotyp
also
vector
traffic
site
inject
region
brain
via
neuron
connect
other
remain
local
thu
target
achiev
collect
site
inject
propens
viru
infect
certain
cell
type
traffic
along
within
neuron
axon
neurit
promot
use
drive
express
rnai
trigger
chronic
dominantli
inherit
disord
may
prefer
silenc
mutant
allel
brain
diseas
highli
preval
diseaselink
polymorph
provid
opportun
allelespecif
silenc
primari
dystonia
caus
common
gag
delet
torsin
one
exampl
disord
sever
diseaselink
snp
present
patient
snp
provid
opportun
diseas
allel
silenc
howev
target
snp
use
rnai
critic
consid
potenti
offtarget
bind
seed
sequenc
small
rna
box
unintend
offtarget
silenc
could
abrog
benefici
effect
leav
wildtyp
allel
intact
huntington
diseas
case
point
preclin
work
anim
model
show
partial
knockdown
allel
huntingtin
toler
provid
clinic
benefit
yet
genotyp
show
snp
huntingtin
may
present
major
patient
huntington
diseas
small
rna
specif
snp
may
moder
high
offtarget
potenti
therefor
test
longterm
toler
vivo
safeti
partial
reduct
express
mutant
wildtyp
allel
one
first
organ
test
effect
rnai
vivo
liver
rnaibas
treatment
metabol
diseas
hypercholesterolaemia
viral
infect
cancer
liver
fibrosi
review
ref
progress
metabol
diseas
preclin
clinic
trial
underway
lower
plasma
ldl
use
sirna
target
express
apolipoprotein
b
apob
proprotein
convertas
subtilisinkexin
type
work
sirna
complex
carrier
embed
liposom
particl
exampl
snalp
data
rodent
nonhuman
primat
show
signific
ldllower
properti
one
first
trial
human
corpor
news
releas
state
snalpformul
apob
sirna
well
toler
highest
dose
newer
formul
show
improv
potenc
nonhuman
primat
develop
liver
also
one
first
organ
target
develop
rnaibas
therapi
cancer
one
studi
use
snalp
target
cell
cycl
protein
crucial
activ
phosphoryl
mani
cell
cycl
protein
inhibit
induc
cell
cycl
arrest
tumour
cell
apoptosi
mice
hepat
tumour
treat
snalpformul
sirna
show
signific
improv
surviv
decemb
technolog
advanc
phase
trial
human
liver
cancer
tabl
anoth
hepat
cancer
applic
snalp
simultan
deliv
sirna
kinesin
spindl
protein
ksp
vascular
endotheli
growth
factor
vegf
ksp
requir
cell
divis
vegf
requir
tumour
cell
growth
earli
sponsor
phase
trial
use
approach
report
evid
rnai
activ
biopsi
tissu
preliminari
report
along
first
report
rnai
activ
exogen
appli
sirna
complex
import
mileston
develop
rnai
deliveri
system
cancer
therapeut
mirna
therapeut
target
identif
misregul
mirna
cellular
transform
mainten
malign
state
profound
implic
cancer
therapi
misregul
gene
mirna
target
gene
silenc
approach
whether
mirna
encod
host
genom
express
oncogen
virus
review
ref
inhibit
oncogen
mirna
regul
multipl
target
might
switch
dozen
cancerpromot
signal
rather
devis
sirna
target
misregul
mirna
research
develop
mirna
spong
provid
altern
bind
platform
mirna
inhibit
abil
bind
suppress
natur
target
fig
earli
exampl
intraven
deliveri
antagomir
chemic
modifi
rna
oligonucleotid
antisens
mirna
primat
model
hcv
infect
oligonucleotid
sequest
inhibit
viru
replic
plasmidand
virusbas
approach
also
use
reduc
endogen
mirna
level
typic
approach
strong
promot
drive
express
sequenc
encod
sever
mirna
target
site
downstream
report
multipl
copi
express
becom
target
bind
mirna
sequest
target
endogen
mrna
addit
develop
describ
substanti
progress
use
gene
silenc
approach
treat
skin
retin
diseas
like
liver
airway
access
tissu
earli
target
preclin
test
exploit
small
rna
biogenesi
gene
silenc
pathway
heart
diseas
either
use
sirna
singl
target
inhibit
action
misregul
mirna
also
yield
promis
result
approach
clinic
trial
addit
util
standalon
strategi
rnai
may
expand
applic
adjuv
multiprong
treatment
set
exampl
target
multidrug
resist
protein
also
known
cancer
cell
may
enhanc
activ
chemotherapeut
host
gene
target
similar
end
cancer
therapeut
anoth
rnai
adjuv
strategi
use
dsrna
oligonucleotid
immunostimulatori
agonist
alongsid
vaccin
case
agonist
enhanc
activ
dna
vaccin
influenza
rnai
therapi
develop
consid
whether
region
deliveri
partial
knockdown
global
deliveri
complet
knockdown
requir
therapeut
result
exampl
former
direct
deliveri
specif
region
brain
parkinson
diseas
contrast
rnai
therapi
cancer
may
requir
deliveri
cancer
cell
anoth
import
issu
yet
resolv
dose
therapeut
rnai
case
cancer
pharmacologist
must
balanc
target
cell
abil
recov
exogen
appli
sirna
antimirna
treatment
practic
consider
patient
complianc
repetit
dose
clinic
success
eventu
cure
requir
treatment
week
month
year
viral
vector
express
system
rnai
overcom
problem
provid
sustain
express
strategi
requir
genom
integr
vector
target
cell
divid
order
overcom
potenti
danger
genom
integr
method
integr
genom
safe
harbour
import
respect
longterm
rnai
viral
vector
therapi
genet
diseas
question
whether
regul
express
requir
help
answer
question
expect
longterm
studi
larg
anim
exampl
nonhuman
primat
yield
valuabl
inform
regard
chronic
applic
inhibitori
rna
variou
platform
consider
although
end
point
trial
obviou
exampl
lower
blood
cholesterol
reduc
tumour
burden
sensit
specif
end
point
alway
clear
chronic
disord
tissu
easili
biopsi
biomark
valid
slightli
decad
advanc
rapidli
rnai
discoveri
understand
molecular
process
drive
small
rna
biogenesi
function
develop
reagent
har
power
rnai
pathway
although
mani
hurdl
remain
use
technolog
therapi
excit
earli
clinic
result
show
far
come
